American Association for Thoracic Surgery/International Society for Heart and Lung Transplantation guidelines on selected topics in mechanical circulatory support

Mechanical  circulatory support (MCS) evolved from an engineering dream to clinical reality during the 1980s when increasing numbers of patients were dying on heart transplant wait lists. Following the Randomized Evaluation of Mechanical Assistance for the Treatment of Congestive Heart Failure Trial,1 the US Food and Drug Administration (FDA) approved a pulsatile implantable left ventricular assist device (LVAD) for long-term implantation in 2002. When the FDA approved the first US continuous flow (CF) LVAD in 2008, the landscape had changed dramatically.
Source: The Journal of Heart and Lung Transplantation - Category: Transplant Surgery Authors: Tags: Adult: Mechanical Circulartory Support: AATS/ISHLT Guidelines on Selected Topics in Mechanical Circulatory Support Source Type: research

Related Links:

This study enrolled an institutional consecutive surgical series of 24 patients with refractory congestive heart failure under peripheral ECLS, related to fulminant myocarditis (n = 15), dilated cardiomyopathy (n = 5), or acute myocardial infarction (n = 4). They were converted to central Y-extracorporeal membrane oxygenation (ECMO,n = 6), extracorporeal ventricular assist device (EC-VAD,n = 12), or pump catheter (n = 6), dependent upon the degree of multiorgan failure. Despite the different degree of multiorgan failure prior to the convers...
Source: Journal of Artificial Organs - Category: Transplant Surgery Source Type: research
Discussion of the Evolutionary Genetics of Aging Thymic Involution Contributes to Immunosenescence and Inflammaging The Potential for Exosome Therapies to Treat Sarcopenia Correlations of Mitochondrial DNA Copy Number and Epigenetic Age Measures Evidence for PASK Deficiency to Reduce the Impact of Aging in Mice The Aging Retina, a Mirror of the Aging Brain Evidence for Loss of Capillary Density to be Important in Heart Disease Aspects of Immune System Aging Proceed More Rapidly in Men Deacetylation of the NLRP3 Inflammasome as a Way to Control Chronic Inflammation Transplantation of Senescent Cells is an ...
Source: Fight Aging! - Category: Research Authors: Tags: Newsletters Source Type: blogs
CONCLUSIONS: HSCT is an important step in the treatment of progressive SSc in Israel. Careful patient selection reduces treatment related morbidity and mortality. PMID: 32043328 [PubMed - in process]
Source: The Israel Medical Association Journal - Category: General Medicine Tags: Isr Med Assoc J Source Type: research
Publication date: July 2019Source: The Annals of Thoracic Surgery, Volume 108, Issue 1Author(s): Ji-ming Sha, Yi Cao, Sheng-song XuAnomalous origin of the pulmonary artery from the ascending aorta can lead to congestive heart failure in infancy, and with advancing age many patients will experience severe pulmonary hypertension. Surgical intervention has high mortality and morbidity risks if this happens. Strategies to manage these patients seem only limited to heart–lung transplantation or lung transplantation. Here, we successfully performed surgical intervention in an adult patient who had anomalous origin of the r...
Source: The Annals of Thoracic Surgery - Category: Cardiovascular & Thoracic Surgery Source Type: research
Fight Aging! provides a weekly digest of news and commentary for thousands of subscribers interested in the latest longevity science: progress towards the medical control of aging in order to prevent age-related frailty, suffering, and disease, as well as improvements in the present understanding of what works and what doesn't work when it comes to extending healthy life. Expect to see summaries of recent advances in medical research, news from the scientific community, advocacy and fundraising initiatives to help speed work on the repair and reversal of aging, links to online resources, and much more. This content is...
Source: Fight Aging! - Category: Research Authors: Tags: Newsletters Source Type: blogs
The intravascular ventricular assist system (iVAS) is a long-term, ambulatory counterpulsation heart assist system designed for long term use in patients with advanced congestive heart failure (aCHF). A feasibility trial has been conducted and early analysis showed several pre-implant parameters, particularly cardiac power efficiency (CPE), could predict hemodynamic success. The data has been reanalyzed with completion of the trial.
Source: The Journal of Heart and Lung Transplantation - Category: Transplant Surgery Authors: Tags: 187 Source Type: research
The objective was to evaluate the role of iVAS as a BTD device.
Source: The Journal of Heart and Lung Transplantation - Category: Transplant Surgery Authors: Tags: 255 Source Type: research
Mortality associated with congestive heart failure continues to be a substantial problem. While in-hospital mortality has declined recently, this same trend has not been replicated in 30-day mortality, an important quality marker for many institutions. Thus, it is important to try to identify patient characteristics that would be predictive of increased mortality in order to target these risk factors to improve 30-day mortality.
Source: The Journal of Heart and Lung Transplantation - Category: Transplant Surgery Authors: Tags: 951 Source Type: research
An intra-aortic balloon pump (IABP) can help optimize and bridge to transplant (BTT) patients with advanced congestive heart failure. We retrospectively reviewed the application and safety of this technique at our center.
Source: The Journal of Heart and Lung Transplantation - Category: Transplant Surgery Authors: Tags: 1147 Source Type: research
Left ventricular non-compaction (LVNC) can present with congestive heart failure and thromboembolic events. Thrombus formation in the left ventricle from LVNC is commonly seen and has resulted in a very cautionary approach for mechanical circulatory support (MCS) for heart failure presentation. Due to continued limitations in availability for donor heart options other than MCS therapy remain limited. The aim of this single center study is to assess freedom from pump thrombosis at 6 months in LVNC.
Source: The Journal of Heart and Lung Transplantation - Category: Transplant Surgery Authors: Tags: 1118 Source Type: research
More News: Cardiology | Cardiovascular & Thoracic Surgery | Congestive Heart Failure | Food and Drug Administration (FDA) | Heart | Heart Failure | Heart Transplant | Lung Transplant | Middle East Health | Transplant Surgery | Transplants